Blood:LncRNA BGLT3调控胎儿γ球蛋白基因的表达

2018-08-28 MedSci MedSci原创

中心点:BGLT3是发育阶段特异性的lncRNA,位于HBG1下游,正性调节γ-球蛋白基因。BGLT3位点和转录本在增加γ球蛋白转录的循环和介质互作中发挥不同的功能。摘要:长链非编码RNAs(lncRNA)参与调控多种细胞生理过程,包括转录,受到越来越多的关注。鉴于lncRNAs具有高度细胞特异性,其可能参与调控不同细胞的独特转录谱,但其潜在机制尚未十分明确。BGLT3,由Aγ-球蛋白(HBG1)

中心点:

BGLT3是发育阶段特异性的lncRNA,位于HBG1下游,正性调节γ-球蛋白基因。

BGLT3位点和转录本在增加γ球蛋白转录的循环和介质互作中发挥不同的功能。

摘要:

长链非编码RNAs(lncRNA)参与调控多种细胞生理过程,包括转录,受到越来越多的关注。鉴于lncRNAs具有高度细胞特异性,其可能参与调控不同细胞的独特转录谱,但其潜在机制尚未十分明确。

BGLT3,由Aγ-球蛋白(HBG1)的下游序列编码的红系lncRNA,在红系细胞中与γ-球蛋白基因共转录。通过CRISPR/Case9敲除BGLT3发现其特异性调控γ-球蛋白基因。研究人员通过敲低或过表达RNA,以及抑制转录来区分转录本与基础序列的功能。

BGLT3位点的转录对γ-球蛋白基因和BGLT3序列之间的循环至关重要。与此相反,BGLT3转录本对γ-球蛋白/BGLT3循环来说可有可无,但会与染色质上的调节复合物相结合。BGLT3位点的操作不影响γ-球蛋白基因与β-球蛋白位点控制区域(LCR)的远程循环互作。

总而言之,BGLT3以发育阶段特异性的方式调节γ-球蛋白转录,与LCR协同增加γ-球蛋白基因启动子上的RNA Pol II(RNA合成酶)的密度,进而促进γ球蛋白转录。


原始出处:

Maria Soledad Ivaldi, et al. Fetal γ-globin genes are regulated by the BGLT3 long non-coding RNA locus. Blood  2018  :blood-2018-07-862003;  doi: https://doi.org/10.1182/blood-2018-07-862003

本文系梅斯医学(MedSci)原创编译,转载需授权!

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (6)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=2005692, encodeId=b9562005692bf, content=<a href='/topic/show?id=6ff1525e13' target=_blank style='color:#2F92EE;'>#CRN#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5257, encryptionId=6ff1525e13, topicName=CRN)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=35fc2500023, createdName=yanjie6253_56072842, createdTime=Tue Sep 04 17:31:00 CST 2018, time=2018-09-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2035173, encodeId=299420351e377, content=<a href='/topic/show?id=5a426866eae' target=_blank style='color:#2F92EE;'>#球蛋白#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=68667, encryptionId=5a426866eae, topicName=球蛋白)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2317301, createdName=xzw113, createdTime=Tue Mar 12 22:31:00 CST 2019, time=2019-03-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1668986, encodeId=09d5166898644, content=<a href='/topic/show?id=c44319269c7' target=_blank style='color:#2F92EE;'>#γ球蛋白#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=19269, encryptionId=c44319269c7, topicName=γ球蛋白)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ccf126484170, createdName=xiaoyeshuang, createdTime=Fri May 03 08:31:00 CST 2019, time=2019-05-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1301897, encodeId=b1f5130189e69, content=<a href='/topic/show?id=b469109e41d' target=_blank style='color:#2F92EE;'>#lncRNA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10974, encryptionId=b469109e41d, topicName=lncRNA)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2317301, createdName=xzw113, createdTime=Thu Aug 30 12:31:00 CST 2018, time=2018-08-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=341739, encodeId=2b52341e3965, content=嗯嗯,学习了。, beContent=null, objectType=article, channel=null, level=null, likeNumber=54, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://cdnapi.center.medsci.cn/medsci/head/2018/07/16/3b24606172648eea459125cb74754afe.jpg, createdBy=6c022216608, createdName=liumin1987, createdTime=Thu Aug 30 08:13:55 CST 2018, time=2018-08-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=341680, encodeId=15cb341680eb, content=学习了,谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=61, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7c592194322, createdName=1209e435m98(暂无昵称), createdTime=Thu Aug 30 04:11:49 CST 2018, time=2018-08-30, status=1, ipAttribution=)]
  2. [GetPortalCommentsPageByObjectIdResponse(id=2005692, encodeId=b9562005692bf, content=<a href='/topic/show?id=6ff1525e13' target=_blank style='color:#2F92EE;'>#CRN#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5257, encryptionId=6ff1525e13, topicName=CRN)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=35fc2500023, createdName=yanjie6253_56072842, createdTime=Tue Sep 04 17:31:00 CST 2018, time=2018-09-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2035173, encodeId=299420351e377, content=<a href='/topic/show?id=5a426866eae' target=_blank style='color:#2F92EE;'>#球蛋白#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=68667, encryptionId=5a426866eae, topicName=球蛋白)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2317301, createdName=xzw113, createdTime=Tue Mar 12 22:31:00 CST 2019, time=2019-03-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1668986, encodeId=09d5166898644, content=<a href='/topic/show?id=c44319269c7' target=_blank style='color:#2F92EE;'>#γ球蛋白#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=19269, encryptionId=c44319269c7, topicName=γ球蛋白)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ccf126484170, createdName=xiaoyeshuang, createdTime=Fri May 03 08:31:00 CST 2019, time=2019-05-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1301897, encodeId=b1f5130189e69, content=<a href='/topic/show?id=b469109e41d' target=_blank style='color:#2F92EE;'>#lncRNA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10974, encryptionId=b469109e41d, topicName=lncRNA)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2317301, createdName=xzw113, createdTime=Thu Aug 30 12:31:00 CST 2018, time=2018-08-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=341739, encodeId=2b52341e3965, content=嗯嗯,学习了。, beContent=null, objectType=article, channel=null, level=null, likeNumber=54, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://cdnapi.center.medsci.cn/medsci/head/2018/07/16/3b24606172648eea459125cb74754afe.jpg, createdBy=6c022216608, createdName=liumin1987, createdTime=Thu Aug 30 08:13:55 CST 2018, time=2018-08-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=341680, encodeId=15cb341680eb, content=学习了,谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=61, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7c592194322, createdName=1209e435m98(暂无昵称), createdTime=Thu Aug 30 04:11:49 CST 2018, time=2018-08-30, status=1, ipAttribution=)]
    2019-03-12 xzw113
  3. [GetPortalCommentsPageByObjectIdResponse(id=2005692, encodeId=b9562005692bf, content=<a href='/topic/show?id=6ff1525e13' target=_blank style='color:#2F92EE;'>#CRN#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5257, encryptionId=6ff1525e13, topicName=CRN)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=35fc2500023, createdName=yanjie6253_56072842, createdTime=Tue Sep 04 17:31:00 CST 2018, time=2018-09-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2035173, encodeId=299420351e377, content=<a href='/topic/show?id=5a426866eae' target=_blank style='color:#2F92EE;'>#球蛋白#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=68667, encryptionId=5a426866eae, topicName=球蛋白)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2317301, createdName=xzw113, createdTime=Tue Mar 12 22:31:00 CST 2019, time=2019-03-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1668986, encodeId=09d5166898644, content=<a href='/topic/show?id=c44319269c7' target=_blank style='color:#2F92EE;'>#γ球蛋白#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=19269, encryptionId=c44319269c7, topicName=γ球蛋白)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ccf126484170, createdName=xiaoyeshuang, createdTime=Fri May 03 08:31:00 CST 2019, time=2019-05-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1301897, encodeId=b1f5130189e69, content=<a href='/topic/show?id=b469109e41d' target=_blank style='color:#2F92EE;'>#lncRNA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10974, encryptionId=b469109e41d, topicName=lncRNA)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2317301, createdName=xzw113, createdTime=Thu Aug 30 12:31:00 CST 2018, time=2018-08-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=341739, encodeId=2b52341e3965, content=嗯嗯,学习了。, beContent=null, objectType=article, channel=null, level=null, likeNumber=54, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://cdnapi.center.medsci.cn/medsci/head/2018/07/16/3b24606172648eea459125cb74754afe.jpg, createdBy=6c022216608, createdName=liumin1987, createdTime=Thu Aug 30 08:13:55 CST 2018, time=2018-08-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=341680, encodeId=15cb341680eb, content=学习了,谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=61, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7c592194322, createdName=1209e435m98(暂无昵称), createdTime=Thu Aug 30 04:11:49 CST 2018, time=2018-08-30, status=1, ipAttribution=)]
  4. [GetPortalCommentsPageByObjectIdResponse(id=2005692, encodeId=b9562005692bf, content=<a href='/topic/show?id=6ff1525e13' target=_blank style='color:#2F92EE;'>#CRN#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5257, encryptionId=6ff1525e13, topicName=CRN)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=35fc2500023, createdName=yanjie6253_56072842, createdTime=Tue Sep 04 17:31:00 CST 2018, time=2018-09-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2035173, encodeId=299420351e377, content=<a href='/topic/show?id=5a426866eae' target=_blank style='color:#2F92EE;'>#球蛋白#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=68667, encryptionId=5a426866eae, topicName=球蛋白)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2317301, createdName=xzw113, createdTime=Tue Mar 12 22:31:00 CST 2019, time=2019-03-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1668986, encodeId=09d5166898644, content=<a href='/topic/show?id=c44319269c7' target=_blank style='color:#2F92EE;'>#γ球蛋白#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=19269, encryptionId=c44319269c7, topicName=γ球蛋白)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ccf126484170, createdName=xiaoyeshuang, createdTime=Fri May 03 08:31:00 CST 2019, time=2019-05-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1301897, encodeId=b1f5130189e69, content=<a href='/topic/show?id=b469109e41d' target=_blank style='color:#2F92EE;'>#lncRNA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10974, encryptionId=b469109e41d, topicName=lncRNA)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2317301, createdName=xzw113, createdTime=Thu Aug 30 12:31:00 CST 2018, time=2018-08-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=341739, encodeId=2b52341e3965, content=嗯嗯,学习了。, beContent=null, objectType=article, channel=null, level=null, likeNumber=54, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://cdnapi.center.medsci.cn/medsci/head/2018/07/16/3b24606172648eea459125cb74754afe.jpg, createdBy=6c022216608, createdName=liumin1987, createdTime=Thu Aug 30 08:13:55 CST 2018, time=2018-08-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=341680, encodeId=15cb341680eb, content=学习了,谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=61, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7c592194322, createdName=1209e435m98(暂无昵称), createdTime=Thu Aug 30 04:11:49 CST 2018, time=2018-08-30, status=1, ipAttribution=)]
    2018-08-30 xzw113
  5. [GetPortalCommentsPageByObjectIdResponse(id=2005692, encodeId=b9562005692bf, content=<a href='/topic/show?id=6ff1525e13' target=_blank style='color:#2F92EE;'>#CRN#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5257, encryptionId=6ff1525e13, topicName=CRN)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=35fc2500023, createdName=yanjie6253_56072842, createdTime=Tue Sep 04 17:31:00 CST 2018, time=2018-09-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2035173, encodeId=299420351e377, content=<a href='/topic/show?id=5a426866eae' target=_blank style='color:#2F92EE;'>#球蛋白#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=68667, encryptionId=5a426866eae, topicName=球蛋白)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2317301, createdName=xzw113, createdTime=Tue Mar 12 22:31:00 CST 2019, time=2019-03-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1668986, encodeId=09d5166898644, content=<a href='/topic/show?id=c44319269c7' target=_blank style='color:#2F92EE;'>#γ球蛋白#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=19269, encryptionId=c44319269c7, topicName=γ球蛋白)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ccf126484170, createdName=xiaoyeshuang, createdTime=Fri May 03 08:31:00 CST 2019, time=2019-05-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1301897, encodeId=b1f5130189e69, content=<a href='/topic/show?id=b469109e41d' target=_blank style='color:#2F92EE;'>#lncRNA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10974, encryptionId=b469109e41d, topicName=lncRNA)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2317301, createdName=xzw113, createdTime=Thu Aug 30 12:31:00 CST 2018, time=2018-08-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=341739, encodeId=2b52341e3965, content=嗯嗯,学习了。, beContent=null, objectType=article, channel=null, level=null, likeNumber=54, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://cdnapi.center.medsci.cn/medsci/head/2018/07/16/3b24606172648eea459125cb74754afe.jpg, createdBy=6c022216608, createdName=liumin1987, createdTime=Thu Aug 30 08:13:55 CST 2018, time=2018-08-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=341680, encodeId=15cb341680eb, content=学习了,谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=61, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7c592194322, createdName=1209e435m98(暂无昵称), createdTime=Thu Aug 30 04:11:49 CST 2018, time=2018-08-30, status=1, ipAttribution=)]
    2018-08-30 liumin1987

    嗯嗯,学习了。

    0

  6. [GetPortalCommentsPageByObjectIdResponse(id=2005692, encodeId=b9562005692bf, content=<a href='/topic/show?id=6ff1525e13' target=_blank style='color:#2F92EE;'>#CRN#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5257, encryptionId=6ff1525e13, topicName=CRN)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=35fc2500023, createdName=yanjie6253_56072842, createdTime=Tue Sep 04 17:31:00 CST 2018, time=2018-09-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2035173, encodeId=299420351e377, content=<a href='/topic/show?id=5a426866eae' target=_blank style='color:#2F92EE;'>#球蛋白#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=68667, encryptionId=5a426866eae, topicName=球蛋白)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2317301, createdName=xzw113, createdTime=Tue Mar 12 22:31:00 CST 2019, time=2019-03-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1668986, encodeId=09d5166898644, content=<a href='/topic/show?id=c44319269c7' target=_blank style='color:#2F92EE;'>#γ球蛋白#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=19269, encryptionId=c44319269c7, topicName=γ球蛋白)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ccf126484170, createdName=xiaoyeshuang, createdTime=Fri May 03 08:31:00 CST 2019, time=2019-05-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1301897, encodeId=b1f5130189e69, content=<a href='/topic/show?id=b469109e41d' target=_blank style='color:#2F92EE;'>#lncRNA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10974, encryptionId=b469109e41d, topicName=lncRNA)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2317301, createdName=xzw113, createdTime=Thu Aug 30 12:31:00 CST 2018, time=2018-08-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=341739, encodeId=2b52341e3965, content=嗯嗯,学习了。, beContent=null, objectType=article, channel=null, level=null, likeNumber=54, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://cdnapi.center.medsci.cn/medsci/head/2018/07/16/3b24606172648eea459125cb74754afe.jpg, createdBy=6c022216608, createdName=liumin1987, createdTime=Thu Aug 30 08:13:55 CST 2018, time=2018-08-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=341680, encodeId=15cb341680eb, content=学习了,谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=61, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7c592194322, createdName=1209e435m98(暂无昵称), createdTime=Thu Aug 30 04:11:49 CST 2018, time=2018-08-30, status=1, ipAttribution=)]
    2018-08-30 1209e435m98(暂无昵称)

    学习了,谢谢分享

    0

相关资讯

Cell Death Dis:研究首次发现Corylin具有抗肿瘤活性

Corylin是一种从补骨脂中提取的生物活性物质,可促进骨骼分化并抑制炎症。到目前为止,仅有少数研究探究了corylin的生物学调节功能,尚未有研究调查其抗肿瘤活性。在这项研究中,我们使用细胞功能分析来分析Corylin在肝细胞癌(HCC)中的抗肿瘤活性。此外,进行全转录组测定以鉴定由corylin调节的下游基因,并且进行功能获得和功能丧失实验以检查上述基因的调节作用。结果发现,corylin可显

Biol Res:lncRNA BANCR上调与结直肠癌淋巴结转移及预后不良相关

越来越多的证据支持长链非编码RNA(lncRNA)在结直肠癌(CRC)的发展、进展和预后中发挥重要作用。然而,关于BRAF激活的非编码RNA(BANCR)在CRC中的临床意义知之甚少。本研究旨在探讨lncRNA BANCR在CRC患者中的临床应用价值。采用定量实时荧光定量PCR检测了106例CRC组织和65例癌旁正常组织中lncRNA BANCR的表达。结果显示,lncRNA BANCR在CRC组

Cell:沉默的“垃圾”基因,可以阻止肿瘤的生长!

在研究了人类基因组未被探索的区域之后,研究人员发现了一种新的非编码基因,它似乎在癌症的发展中起着重要作用。该基因位于基因组的一个区域,不包含制造蛋白质的指令。有一次,有人认为这个非编码区只是无关紧要的“垃圾”。然而,随着技术的进步,越来越多的基因被发现在这个“暗物质”中,这对健康和疾病都是重要的。在《细胞》杂志,科学家报告说,虽然新的基因并没有编码蛋白质,但它对癌细胞有“直接影响”,他们发现沉默可

Hum Mol Genet:脆性X智力低下蛋白调节神经元轴突发育的研究取得新进展

脆性X染色体综合症(Fragile X syndrome, FXS)是常见的遗传性智力障碍疾病,由脆性X智力低下蛋白(Fragile X mental retardation protein,FMRP)功能缺失所引起。FMRP作为RNA结合蛋白,能够与大量的神经发育相关基因的mRNA直接结合并调控蛋白合成及功能,进而影响神经元树突及树突棘发育和突触可塑性。目前的研究提示,长链非编码RNA (Lon

Biosci Rep:LncRNA DANCR通过抑制lncRNA-LET促进胃癌细胞的迁移和侵袭

胃癌(GC)是最常见的胃肠道恶性肿瘤之一。长链非编码RNA(lncRNA)DANCR是最新鉴定的致癌lncRNA。然而,DANCR在GC方面的功能作用和分子机制尚不清楚。在本研究中,我们研究了DANCR在GC细胞迁移和侵袭中的生物学功能和潜在机制。结果显示,DANCR的敲低抑制了GC细胞的迁移和侵袭,而DANCR的过表达则表现出相反的效果。进一步的研究表明,lncRNA-LET是DANCR的真正靶

J Periodontal Res: 长非编码RNA相关内源性RNA网络在牙周炎中的整合分析

长非编码RNA(lncRNA)在调节牙周炎的各种生物过程中起着关键和复杂的作用。该生物信息学研究旨在通过整合lncRNA,miRNA和mRNA表达构建竞争性内源RNA(ceRNA)网络。